Genmab A/S ADS (GMAB)
GMAB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1434265/000143426526000014/0001434265-26-000014-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GMAB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Denmark |
| IPO year | 2019 |
| SEC CIK | 0001434265 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.7B |
| Net income | $963.0M |
| Operating income | $1.1B |
| Net margin | 25.9% |
| Operating margin | 28.6% |
| Revenue growth | +19.2% |
| Cash | $1.7B |
| Total assets | $12.9B |
| P/E (computed) | 33.4× |
| P/S (computed) | 8.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-02-17 |
| Cash and burn | $1.7B cash; operating cash flow $296.5M a quarter. | Report 2025-12-31 |
| Shares outstanding | 642,384,080 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte Statsautoriseret Revisionspartnerselskab, Copenhagen, Denmark | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $3.7B | $963.0M | $1.2B | $1.7B | $5.3B | $3.7B | 20-F 2026-02-17 |
| FY 2024 2024-12-31 | $3.1B | $1.1B | $1.1B | $1.4B | $0 | $3.1B | 20-F 2026-02-17 |
| FY 2023 2023-12-31 | $2.4B | $631.0M | $1.1B | $2.2B | $0 | $2.4B | 20-F 2026-02-17 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2019-07-19 |
| Latest annual report | 20-F | 2026-02-17 |
| Latest quarterly / interim | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 573 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.2% |
| 1 month | +40.5% |
| 3 months | +63.9% |
| Year to date | +66.8% |
| 1 year | +69.9% |
| From 52-week high | -10.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ZTS | Zoetis Inc. | $84.39 | +0.68% | $34.3B |
| ROIV | Roivant Sciences Ltd. Common Shares | $38.61 | -2.33% | $28.0B |
| INSM | Insmed Incorporated | $122.88 | +1.42% | $27.0B |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | $68.53 | -1.13% | $39.3B |
| UTHR | United Therapeutics Corporation | $587.88 | -0.56% | $25.0B |
| VTRS | Viatris Inc. | $20.74 | -0.38% | $23.8B |
| ONC | BeOne Medicines Ltd. | $411.29 | -1.26% | $47.0B |
| ALNY | Alnylam Pharmaceuticals Inc. | $159.73 | -3.22% | $21.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier